Efficacy Of Repatha® Across High-Risk Patient Populations Reinforced At ACC.21
Amgen today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular events, including complex revascularization procedures. Additional abstracts to be presented include a simulation comparing the impact … Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® (evolocumab) open label extension trial...
Source: investingnews.com